Product Description
For COVID-19 (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05162365)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Innovent Biologics (Suzhou) Co. Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: COVID-19
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05172141 |
CIBI314B201 | P2 |
Terminated |
COVID-19 |
2022-08-31 |
57% |
2023-03-02 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05162365 |
CIBI314A201 | P2 |
Terminated |
COVID-19 |
2022-06-29 |
72% |
2023-12-19 |
Recent News Events
Date |
Type |
Title |
|---|